[en] A 6-kilobase fragment extending at the 5'-end of the c-erbB2 protooncogene was isolated from a normal human lymphocyte genomic DNA library. The full-length fragment and five subfragments with identical 3'-ends were obtained by progressive unidirectional deletion from the 5'-end and were cloned in front of the luciferase reporter gene. The hybrid genes were analyzed for transcriptional activity in human mammary cell lines synthesizing low (HBL-100 and T-47D), moderate (MDA-MB-453), or high (BT-474) amounts of the c-erbB2 mRNA and were also analyzed in HeLa cells. Gene-specific expression was observed, indicating the presence of multiple cis-acting sequences in the c-erbB2 promoter. A major negative element is located in the -2- to -4-kilobase region. It is flanked on both sides by positive elements that display enhanced transcriptional activity in the BT-474 tumor cells only. While predominant in the low-expressing cells, the effect of the repressor appears to be overcome by the distal transactivator in the high-expressing BT-474 cells, resulting in a 15 to 50 times increase in luciferase activity relative to the HBL-100 and T-47D cells, respectively. Cell-specific expression relies on the trans-acting factors present in the different cell lines. The formation of cell-specific protein-DNA complexes was demonstrated by gel retardation assay.
Schcchter, A.L., Hung, M.C., Vaidynathan, L., Weinberg, R.A., Yang-Feng, T.L., Francke, U., Ullrich, A., and Coussens, L. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science (Washington DC), 229: 976-978, 1985.
Yarden, Y., and Weinberg, R.A. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc. Natl. Acad. Sci. USA, 86: 3179-3183, 1989.
Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., and Lippman, M.E. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p. 85erbB2. Science (Washington DC), 249: 1552-1555, 1990.
Davis, J.G., Hamuro, J., Shim, C.Y., Samanta, A., Greene, M.I., and Dobashi, K. Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium. Biochem. Biophys. Res. Commun., 179: 1536-1542, 1991.
Dobashi, K., Davis, J.G., Mikami, Y., Freeman, J.K., Hamuro, J., and Greene, M.K. Characterization of a neu/c-erbB2 protein-specific activating factor. Proc. Natl. Acad. Sci. USA, 88: 8582-8586, 1991.
Tarakhovsky, A., Zaichuk, T., Prassolov, V., and Butenko, Z.A. A 25 kDa polypeptide is the ligand for p. 85neu and is secreted by activated macrophages. Oncogene, 6: 2179-2186, 1991.
Yarden, Y., and Peles, E. Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry, 30: 3543-3550, 1991.
Lupu, R., Colomer, R., Kannan, B., and Lippman, M.E. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc. Natl. Acad. Sci. USA, 892: 287-2291, 1992.
Pelcs, E., Bacus, S.S., Koski, R.A., Lu, H.S., Wen, D., Odgcn, S.G., Ben Levy, R., and Yarden, Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell, 69: 205-216, 1992.
Wen, D., Peles, E., Cupples, R., Suggs, S.V., Bacus, S.S., Luo, Y., Trail, G., Hu, S., Subiger, S.M., Levy, R.B., Koski, R.A., Lu, H.S., and Yarden, Y. Neu differentiating factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell, 69: 559-572, 1992.
Peles, E., Ben-Levy, R., Tzahar, E., Liu, N., Wen, D., and Yarden, Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggest complex ligand-receptor relationships. EMBO J., 12: 961-971, 1993.
Holmes, W.E., Sliwkowski, M.X., Akita, R.W., Henzel, W.J., Lee, J., Park, J.W., Yansura, D., Abadi, N., Raab, H., Lewis, G.D., Shepard, H.M., Kuang, W.J., Wood, W.I., Goeddel, D.V., and Vandlen, R.L. Identification of heregulin, a specific activator of p. 85erbB2. Science (Washington DC), 256: 1205-1210, 1992.
Matsuda, S., Kadowaki, Y., Ichino, M., Akiyama, T., Toyoshima, K., and Yamamoto, T. 17β-Estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc. Natl. Acad. Sci., USA, 90: 10803-10807, 1993.
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., and Press, M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J.T., Dodge, R., Clarke-Pearson, D.L., Marks, P., McKenzie, S., Yin, S., and Bast, R.C., Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
Kraus, M.H., Popescu, N.C., Amsbaugh, S.C., and King, C.R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6: 605-610, 1987.
Perren, T.J. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br. J. Cancer, 63: 328-332, 1991.
Press, M.F., Pike, M.C., Chazin, V.R., Hung, G., Udove, J.A., Markowicz, M., Danyluk, J., Godolphin, W., Sliwkowski, M., Akita, R., Paterson, M.C., and Slamon, D.J. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res., 53: 4960-4970, 1993.
Pasleau, F., Grooteclaes, M., and Gol-Winkler, R. Using a molecular titration assay to quantitate and characterize the c-erbB2 mRNA synthesized in human mammary adenocarcinoma cell lines. Arch. Int. Physiol. Biochem., 98: 40, 1990.
Pasleau, F., Grooteclaes, M., and Gol-Winkler, R. Expression of the c-erbB2 gene in the BT-474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene, 8: 849-854, 1993.
Hollywood, D.P., and Hurst, H.C. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J., 12: 2369-2375, 1993.
Yu, D., Suen, T.G., Yan, D.H., Chang, L.S., and Hung, M.C. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc. NaU. Acad. Sci. USA, 87: 4499-4503, 1990.
Suen, T.C., and Hung, M.C. c-myc reverses neu-induced transformed morphology by transcriptional repression. Mol. Cell. Biol., 11: 354-362, 1991.
Yan, D.H., and Hung, M.C. Identification and characterization of a novel enhancer for the rat neu promoter. Mol. Cell. Biol., 11: 1875-1882, 1991.
White, M.R.A., and Hung, M.C. Cloning and characterization of the mouse neu promoter. Oncogene, 7: 677-683, 1992.
Ishii, S., Imamoto, F., Yamanashi, Y., Toyoshima, K., and Yamamoto, T. Characterization of the promoter region of the human c-erbB-2 protooncogene. Proc. Natl. Acad. Sci. USA, 84: 4374-4378, 1987.
Tal, M., King, C.R., Kraus, M.H., Ullrich, A., Schlessinger, J., and Givol, D. Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation. Mol. Cell. Biol., 7: 2597-2601, 1987.
Hudson, L.G., Erlt, A.P., and Gill, G.N. Structure and inducible regulation of the human c-erbB2/neu promoter. J. Biol. Chem., 265: 4389-4393, 1990.
Pasleau, F., Dijkmans, H., Bertrand, B., and Gol-Winkler, R. Cloning and sequencing the upstream regulatory region of the c-erbB2 gene. Arch. Int. Physiol. Biochem., 98: 2, 1990.
Nordeen, S.K. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques, 6: 454-456, 1988.
Luckow, B., and Schutz, G. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoter and regulatory elements. Nucleic Acids Res., 15: 5490, 1987.
Nguyen, V.T., Morange, M., and Bensaude, O. Firefly luciferase luminescence assays using scintillation counters for quantitation in transfected mammalian cells. Anal. Biochem., 171: 404-408, 1988.
Armitage, P., and Berry, G. Statistical Methods in Medical Research. London: Blackwell, 1989.
Dignam, G.D. Preparation of extracts from higher eukaryotes. Methods Enzymol., 182: 194-203, 1990.
Farr, A., and Roman, A. A pitfall of using a second plasmid to determine transfection efficiency. Nucleic Acids Res., 20: 920, 1992.
Bargmann, C.I., Hung, M.G., and Weinberg, R.A. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. Cell, 45: 649-657, 1986.
Lemoine, N.R., Staddon, S., Dickson, C., Barnes, D.M., and Gullick, W.J. Absence of activating point mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene, 5: 237-239, 1990.
Di Fiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, G R., and Aaronson, A.A. erbB2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Washington DC), 237: 178-182, 1987.
Hudziak, R.M., Schlessinger, J., and Ullrich, A. Increased expression of the putative growth factor receptor p. 85HER2 causes transformation and tumorigenesis of NIH3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
Guy, C.T., Webster, M.A., Schaller, M., Parsons, T.J., Cardiff, R.D. and Muller, W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA, 89: 10578-10582, 1992.
Schroeter, C.A., De Potter, C.R., Rathsmann, K., Willighagen, R.G.J., and Greep, J.C. c-erbB-2 positive breast tumors behave more aggressively in the first years after diagnosis. Br. J. Cancer, 66: 728-734, 1992.
Lonardo, F., Di Marco, E., King, C.R., Pierce, J.H., Segatto, O., Aaronson, S.A., and Di Fiore, P.P. The normal erbB2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol., 2: 992-1003, 1990.
Wildenhaim, Y., Pawson, T., Blackstein, M.E., and Andrulis, I.L. p. 85neu is phosphorylated on tyrosine in human breast tumors which overexpress neulerbB2. Oncogene, 5: 879-883, 1990.
Russell, K.S., and Hung, M.C. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res., 52: 6624-6629, 1992.
Zhao, X.Y., and Hung, M.C. Negative autoregulation of the neu gene is mediated by a novel enhancer. Mol. Cell. Biol., 12: 2739-2748, 1992.
Press, M.F., Cordon-Cardo, C., and Slamon, D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.
Suen, T.C., and Hung, M.C. Multiple cis- and trans-acting elements involved in regulation of the neu gene. Mol. Cell. Biol., 10: 6306-6315, 1990.
Yan, D.H., Marin, M.C., and Hung, M.C. Differential expression of the neu oncogene in mouse liver and pancreatic cell lines. Biochem. Biophys. Res. Commun., 186: 363-370, 1992.
Antoniotti, S., Maggiora, P., Dati, C., and De Bortoli, M. Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur. J. Cancer, 28: 318-321, 1992.
Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and De Bortoli, M. Inhibition of c-erbB2 oncogene expression by estrogens in human breast cancer cells. Oncogene, J: 1001-1006, 1990.
De Bortoli, M., Dati, C., Antoniotti, S. Maggiora, P., and Sapei, L. Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. J. Steroid Biochem. Mol. Biol., 43: 21-25, 1992.
Read, L.D., Keith, D., Slamon, D.J., and Katzenellenbogen, S. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p. 85 protein expression in human breast cancer cell lines. Cancer Res., 50: 3947-3951, 1990.
